Tag Archives: EC

Innovators: Take a Leaf from the Generic Industry Book

By Guest Blogger | Published: February 1, 2011
No-one can accuse the European generic industry of indolence. It supplies huge quantities of medicines to European healthcare suppliers — its volume is estimated at around a half of the market. It is accounting for a growing share of marketing authorization applications in Europe. And its industry association, the EGA, has turned it from being [...]
Posted in Europe, Regulatory, healthcare | Also tagged , , , , , , , | Leave a comment

And What Exactly is a Stakeholder?

By Julian Upton | Published: August 19, 2010
Pharma’s uncritical use of the word ‘stakeholder’ has increased to the point where it can refer to almost anyone connected to the industry. But this can have serious consequences, warns Reflector. Like it or not (and frankly, I don’t), stakeholders are here to stay in European pharmaceutical affairs. Don’t get me wrong. I’ve no objection to [...]
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , , , , , , , | 1 Comment

The EC Admonishes European Pharma, European Pharma Celebrates

By Julian Upton | Published: July 17, 2009
Despite the rhetoric, the climax of the European Commission’s antitrust investigations — instigated with dawn raids on the major pharma companies by EC Competition Commissioner Neelie Kroes last year — has been more of a whimper than a bang. Pharm Exec Europe’s EU correspondent Reflector goes so far as to say “Big Pharma is not opening [...]
Posted in Global, Regulatory | Also tagged , , , , , , , , | Leave a comment